Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zantac patent appellate court ruling expected by end of March.

This article was originally published in The Tan Sheet

Executive Summary

GLAXO/NOVOPHARM ZANTAC APPEAL DECISION LIKELY BY MARCH, based on the expedited handling being given by the D.C. federal appeals court to the patent case for the H2 antagonist. Although no schedule has been set by the court, Novopharm said it expects oral arguments in December or January and the court to render its decision by the end of March. Glaxo is appealing a Raleigh, N.C. federal court ruling that would allow Novopharm to launch a generic version of the prescription ulcer medication ranitidine (Form 1) in July 1997 ("The Tan Sheet" July 15, p. 5).
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086309

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel